Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan
Study Identifier:
AA-HPP-409
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Asfotase Alfa
Date
Jun 2015 - Nov 2015
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A+ years
Requirements Information
Sex
Female & Male
Age
N/A+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Asfotase Alfa
Date
Jun 2015 - Nov 2015
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A+ years years
Requirements Information
Protocol Summary
This is a multicenter study in Japan. Eleven sites which have already participated in the investigator-initiated clinical study (Early Access Program) will participate in this study.The objective of this study is to gain further information on the safety and efficacy of treatment with asfotase alfa.
Trial Locations
No locations found.